Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)

Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.

CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of 

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months ended December 31, 2021.

  During Tuesday, 40 stocks hit new 52-week lows.

  During Friday, 48 stocks hit new 52-week lows.

  On Wednesday, 22 companies hit new 52-week lows.

  On Wednesday, 35 companies reached new 52-week lows.

By Ernest Dela Aglanu, Benzinga

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.

Sign up for this week’s All Access giveaway here!  Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022.

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.